HLA-DR BINDING PEPTIDES AND THEIR USES
The present invention provides HLA-DR (MHC class II) binding peptides derived from the ovarian/breast cancer associated antigens, Human Epidermal Growth Factor Receptor 2 (HER-2/neu), Carcinoembryonic Antigen (CEA), Insulin Growth Factor Binding Protein 2 (IGFBP-2), and Cyclin D1. The immunogenic peptides can be used in cancer vaccines.
1 - 37 . (canceled)
38 . A composition comprising an isolated HLA-DR binding peptide selected from the group consisting of the peptides listed in Table 1.
39 . The composition of claim 38 , further comprising a second HTL-inducing peptide.
40 . The composition of claim 38 , further comprising a CTL peptide.
41 . The composition of claim 38 , further comprising a lipid.
42 . The composition of claim 38 , further comprising a liposome.
43 . The composition of claim 38 , wherein said peptide is linked to a spacer molecule.
44 . The composition of claim 38 , further comprising a carrier.
45 . The composition of claim 38 , further comprising an antigen presenting cell.
46 . A composition comprising at least one HLA-DR binding peptide thirty residues or less in length, wherein said peptide comprises an HTL epitope selected from any one of the HTL epitopes listed in Table 1, and admixtures thereof.
47 . The composition of claim 46 , wherein said composition comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54 or 55 peptides.
48 . The composition of claim 46 , comprising at least two Carcinoembryonic Antigen (CEA) HTL peptides, at least two Cyclin D1 HTL peptides, at least two Human Epidermal Growth Factor Receptor 2 (HER-2/neu) HTL peptides, and at least two Insulin Growth Factor Binding Protein 2 (IGFBP-2) HTL peptides.
49 . The composition of claim 46 , consisting of two Carcinoembryonic Antigen (CEA) HTL peptides, at least two Cyclin D1 HTL peptides, at least two Human Epidermal Growth Factor Receptor 2 (HER-2/neu) HTL peptides, and at least two Insulin Growth Factor Binding Protein 2 (IGFBP-2) HTL peptides.
50 . The composition of claim 46 , comprising at least two peptides selected from the group consisting of: HER-2/neu p59, HER-2/neu p83, HER-2/neu p88, HER-2/neu p422, HER-2/neu p885, CEA p24, CEA p75, CEA p176, CEA p423, CEA p488, CEA p650, CEA p663, IGFBP-2 p17, IGFBP-2 p22, IGFBP-2 p249, IGFBP-2 p293, Cyclin D1 p3, Cyclin D1 p49, Cyclin D1 p53, Cyclin D1 p98, Cyclin D1 p137, Cyclin D1 p145, Cyclin D1 p174, and Cyclin D1 p199.
51 . A composition comprising at least one HLA-DR binding peptide thirty residues or less in length, wherein said peptide comprises an HTL epitope selected from any one of the HTL epitopes listed in Table 2, and admixtures thereof.
52 . The composition of claim 51 , wherein said composition comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54 or 55 peptides.
53 . The composition of claim 51 , comprising at least two Carcinoembryonic Antigen (CEA) HTL peptides, at least two Cyclin D1 HTL peptides, at least two Human Epidermal Growth Factor Receptor 2 (HER-2/neu) HTL peptides, and at least two Insulin Growth Factor Binding Protein 2 (IGFBP-2) HTL peptides.
54 . The composition of claim 51 , consisting of two Carcinoembryonic Antigen (CEA) HTL peptides, at least two Cyclin D1 HTL peptides, at least two Human Epidermal Growth Factor Receptor 2 (HER-2/neu) HTL peptides, and at least two Insulin Growth Factor Binding Protein 2 (IGFBP-2) HTL peptides.
55 . The composition of claim 51 , comprising at least two peptides selected from the group consisting of: HER-2/neu p59, HER-2/neu p83, HER-2/neu p88, HER-2/neu p422, HER-2/neu p885, CEA p24, CEA p75, CEA p176, CEA p423, CEA p488, CEA p650, CEA p663, IGFBP-2 p17, IGFBP-2 p22, IGFBP-2 p249, IGFBP-2 p293, Cyclin D1 p3, Cyclin D1 p49, Cyclin D1 p53, Cyclin D1 p98, Cyclin D1 p137, Cyclin D1 p145, Cyclin D1 p174, and Cyclin D1 p199.